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In this multicenter, single-arm, phase II study, the efficacy and safety of ibrutinib
were examined in Japanese patients with relapsed or refractory mantle cell lym-
phoma (MCL). Patients (age ≥20 years) with relapsed or refractory MCL who had
progressed after receiving at least one prior treatment regimen, were enrolled.
Patients were treated with oral ibrutinib (560 mg once daily; 28-day cycle) until
disease progression (or relapse), unacceptable toxicity, or study end. The primary
end-point was overall response rate. Secondary end-points included duration of
response (DOR), time to response, progression-free survival (PFS), overall survival,
and safety. Of the 16 patients who received treatment, 5 patients discontinued
the study (progressive disease, 4; sepsis, 1). Median duration of ibrutinib expo-
sure was 6.5 months (range, 2.8–8.3 months). The overall response rate was
87.5% (90% confidence interval, 65.6–97.7; complete response = 2 [12.5%]; partial
response = 12 [75.0%]). Median time to response for all responders (n = 14) was
1.8 months (range, 0.7–5.3 months). The median DOR and PFS were not estimable
due to censoring (range: DOR, 1.1–6.4+ months; PFS, 2.8–8.0+ months). Overall
survival data were immature due to the limited observation period. A total of 8/
16 patients (50%) had at least one grade 3 adverse event (AE), and 5 (31.3%)
patients reported serious AEs. The most commonly reported AEs were diarrhea
and stomatitis (37.5% each), platelet count decrease (31.3%), and anemia (25%).
Overall, orally administered single agent ibrutinib was efficacious with an accept-
able safety profile in Japanese patients with relapsed or refractory MCL. Clinical
trial registration NCT02169180 (ClinicalTrials.gov).
M antle cell lymphoma is an incurable subtype of B-cellnon-Hodgkin’s lymphoma that often responds poorly to
chemotherapy and has a high relapse rate. The hallmark of
MCL is the translocation t(11;14) (q13;q32), which causes
overexpression of the cell cycle regulator cyclin D1.(1) Mantle
cell lymphoma is a rare condition and accounts for approxi-
mately 2–3% of all malignant lymphoma cases in Japan.(2)
Intensive chemotherapy followed by autologous stem cell
transplant is the treatment of choice for younger and fit
patients.(3) However, the majority of MCL patients are older
(median age of 65 years at diagnosis) and ineligible for inten-
sive treatment approaches.(4) Moreover, relapse is common
with a high mortality rate among these patients.(5) Also, at
relapse, the quality and durability of response to salvage treat-
ment is inferior to that achieved with front-line therapy.(6) Sev-
eral agents like bortezomib, bendamustine, and fludarabine
have been approved for the treatment of relapsed or refractory
MCL in Japan, which have shown efficacy,(7–9) but the high
incidence of toxicities may be a concern.(6,10,11)
Ibrutinib has been approved by the US FDA and European
Medical Agency for the treatment of patients with MCL who
have received at least one prior therapy.(12,13) Results from piv-
otal phase II(5,14) and phase III(15) studies undertaken in Europe,
South and North America, Korea and Taiwan with relapsed
MCL, indicated favorable efficacy and safety of ibrutinib.(14) A
phase I study carried out in Japanese patients with relapsed or
refractory B-cell malignancies, including two MCL patients,
showed acceptable efficacy and safety profiles of ibrutinib.(16)
Therefore, this phase II study was undertaken to evaluate the
efficacy and safety of ibrutinib in Japanese patients with
relapsed or refractory MCL. We present the data obtained up
to the cut-off date, April 30, 2015.
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Materials and Methods
Patients. Japanese patients aged 20 years or older with histo-
logically confirmed, previously treated (1–5 prior lines of ther-
apy) MCL, at least one measurable site of disease (Revised
Response Criteria for Malignant Lymphoma),(17) and Eastern
Cooperative Oncology Group (ECOG) PS of 0 or 1 were
enrolled (detailed information on selection criteria is provided
in Doc. S1).
The study protocol was approved by the local Independent
Ethics Committees of participating institutions, and the study
was carried out in accordance with the ethical principles origi-
nating in the Declaration of Helsinki, the International Confer-
ence on Harmonization Good Clinical Practice guidelines,
applicable regulatory requirements, and in compliance with the
protocol. All participants provided written informed consent to
participate in the study.
Study design. This was a multicenter, single-arm, phase II
study carried out at 11 sites in Japan. The study consisted of a
screening phase, a treatment phase, and a post-treatment fol-
low-up phase (Fig. 1). The 30-day screening phase was fol-
lowed by the treatment phase consisting of a 28-day cycle of
self-administration of the study drug. During this phase,
patients received 560 mg oral ibrutinib once daily until disease
progression (or relapse if the patient achieved CR), occurrence
of unacceptable toxicity, or study end, whichever occurred
first. Doses were held or reduced on the basis of the severity
and the outcome of toxicity. Dose re-escalation after reduction
for toxicity was not allowed. Patients who discontinued the
study treatment entered the post-treatment follow-up phase.
Mantle cell lymphoma diagnosis of each patient was con-
firmed by the central pathology review. Disease assessments
were scheduled throughout the treatment phase to assess effi-
cacy every 8 weeks up to 24 weeks after start of study treat-
ment, thereafter every 12 weeks. The clinical cut-off for the
primary analysis was defined as the time point at which all
patients had completed the efficacy assessment on day 1 of
cycle 7 or had been discontinued from treatment prior to com-
pletion of the assessment on day 1 of cycle 7. The data col-
lected up to this cut-off was included in this report. Patients
will continue to be followed until study end, defined as 2 years
after the last patient was enrolled, the time at which marketing
approval is expected to be received from the Ministry of
Health, Labor and Welfare in Japan, or the time at which the
sponsor terminates the study.
An IRC performing efficacy assessments based on the
Revised Response Criteria for Malignant Lymphoma(13) and a
safety monitoring committee, independent of the sponsor and
study sites, were established for the primary end-point and
safety assessments. The primary end-point of the study was
IRC-assessed ORR. Secondary end-points were DOR, TTR,
PFS, OS, and the safety of ibrutinib.
Concomitant medication. Standard supportive care therapies
(e.g., antiemetics and antidiarrheal) needed for the manage-
ment of symptoms were permitted during the study, as clini-
cally indicated. Systemic chemotherapy, anticancer
immunotherapy, systemic use of corticosteroids, experimental
therapy, and radiotherapy were prohibited during the study.
Efficacy assessments. The ORR was defined as the proportion
of evaluable patients who achieved CR or PR. Other efficacy
end-points included DOR (date of initial documentation of a
response [CR or PR] to the date of first documented evidence
of progressive disease [or relapse for patients who experienced
CR during the study] or death), TTR, PFS (measured from the
date of first dose to the date of the first observation of either
disease progression, relapse from CR, or death), and OS (time
between first dose and death of all cause).
Safety assessments. Safety assessments included physical
examinations, vital signs, laboratory safety, ECOG criteria for
PS, and monitoring AEs. Adverse events were graded using
Common Terminology Criteria for Adverse Events version
4.03.
Statistical analysis. Comparing a clinical threshold value of
20% to the lower bound of the exact 90% CI of the estimate,
efficacy was claimed when the lower bound was above the
threshold. Assuming a 10% drop-out rate, 16 patients were to
be enrolled to accumulate 14 response-evaluable patients.(5)
The efficacy analysis was based on the response-evaluable
population, defined as all enrolled patients who had a
Fig. 1. Study design and patient disposition in this
phase II study evaluating efficacy and safety of
ibrutinib in Japanese patients with relapsed or
refractory mantle cell lymphoma (MCL).
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confirmed diagnosis of MCL by the central pathology review,
received at least one dose of ibrutinib, and had at least one
adequate post-baseline disease assessment. Kaplan–Meier
methodology was used to estimate DOR and PFS. Analyses of
DOR, TTR, PFS, and OS were carried out at the same cut-off
as the ORR. All treated patients were included in the safety
evaluations.
Relative dose intensity (%) was defined as 100 times the
total cumulative dose divided by the duration of exposure
(days) and 560. The duration of exposure (months) was
defined as the last dosing date minus the first dosing date plus
1, divided by 365.25 and multiplied by 12.
Results
Patient group. Of the 19 patients screened, 16 received at
least one dose of ibrutinib (Fig. 1). Most of the patients were
men (75.0%) with a median age of 72 years (range, 55–
83 years). A total of 12 patients (75.0%) had an ECOG PS of
0. The median number of prior treatments was 2.5 (range, 1–
4) (Table 1). Four patients (25.0%) had refractory MCL (pri-
mary refractory, 1; relapsed, 12; relapsed and refractory, 3). At
the time of clinical data cut-off, 11 patients (68.8%) were still
receiving protocol treatment and 5 patients had discontinued
the study (progressive disease, 4; sepsis, 1).
Extent of exposure. The median duration of ibrutinib
exposure until cut-off was 6.5 months (range, 2.8–8.3 months).
The median relative dose intensity was 99.6% (range,
47.9–100.0%).
Efficacy results. The lower limit of exact 90% CI of the
observed ORR exceeded the predefined threshold value (20%),
indicating the efficacy of ibrutinib. The ORR, as assessed by
the IRC, was 87.5% (90% CI, 65.6–97.7; CR = 2 [12.5%];
PR = 12 [75%]). As assessed by the investigator, a total of 15/
16 patients achieved objective responses which contributed to
93.8% ORR (90% CI, 73.6–99.7; CR = 1 [6.3%]; PR = 14
[87.5%]) (Table 2).
The median TTR by IRC assessment for all responders
(n = 14) was 1.8 months (range, 0.7–5.3 months). The median
DOR and PFS by IRC were not estimable due to censoring
(range: DOR, 1.1–6.4+ months; PFS, 2.8–8.0+ months). Simi-
larly, the follow-up period was not sufficient to estimate the
median OS. All patients showed reduction in the sum of the
product of the diameters of measurable lesions from baseline
(Fig. 2).
Safety results. All patients experienced at least one AE. The
most common AEs were diarrhea and stomatitis (n = 6, 37.5%
each), decrease in platelet count (n = 5, 31.3%), and anemia
(n = 4, 25.0%). Eight patients (50.0%) had at least one AE of
toxicity grade 3 or higher. Non-hematological grade 3 or
higher AEs included disease progression (n = 3, 18.8%), sep-
sis, hypokalemia, hyperuricemia, retinal vascular disorder,
arrhythmia, renal impairment, and hypertension (n = 1, 6.3%
each). The investigator considered the ongoing hypertension as
more likely a causative factor for retinal vascular disorder.
Table 1. Demographics and baseline characteristics of Japanese
patients with relapsed or refractory mantle cell lymphoma treated
with ibrutinib (all treated population, n = 16)
Items Statistics, N = 16









Mean (SD) 58.34 (11.59)
Median (range) 55.3 (38.4–85.0)
Duration of disease, months
Mean (SD) 59.84 (35.563)
Median (range) 50.64 (9.7–118.0)




Mean (SD) 2.3 (1.2)
Median (range) 2.5 (1–4)
ECOG PS, n (%)
0 12 (75.0)
1 4 (25.0)
ECOG PS, Eastern Cooperative Oncology Group performance status.
Table 2. Efficacy assessment of ibrutinib in Japanese patients with
relapsed or refractory mantle cell lymphoma, carried out by the
Independent Review Committee (response-evaluable population,
n = 16)
Parameter Statistics, n = 16
Primary end-point





ORR (CR or PR) 14 (87.5)
Exact 90% CI (65.6–97.7)
Secondary end-points
Duration of response, months, n (%)
Responder (CR or PR) 14
Progressed or died, event 2 (14.3)
Censored 12 (85.7)
Median (95% CI) NE (2.79–NE)
Range (1.1–6.4+)
3-months duration rate (95% CI) 0.83 (0.47–0.96)
6-months duration rate (95% CI) 0.83 (0.47–0.96)
Time to initial response,† months
Responder (CR or PR) 14
Median 1.84
Range 0.7–5.3




Progression-free survival, months, n (%)
Progressed or died, event 2 (12.5)
Censored 14 (87.5)
Median (95% CI) NE (NE–NE)
Range (2.8–8.0+)
6-months PFS rate (95% CI) 0.88 (0.59–0.97)
†Derived for subjects who achieved complete response (CR) or partial
response (PR). ‡Derived for subjects who achieved CR. +, Censored
observation; CI, confidence interval; PD, progressive disease; ORR,
overall response rate; NE, not estimable; PFS, progression-free survival.
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Anemia, leukocytosis, neutropenia, and increase in lymphocyte
count (n = 1, 6.3% each) were of grade 3 or higher hemato-
logical AEs (Table 3). Decrease in lymphocyte count was
observed in one patient (6.3%), which was estimated as non-
severe (<grade 3). Hemorrhagic events were reported in 5
(31.3%) patients: contusion (n = 2, 12.5%), anal hemorrhage
(n = 1, 6.3%), epistaxis (n = 1, 6.3%), hematuria (n = 1,
6.3%), subcutaneous hemorrhage (n = 1, 6.3%), mouth hemor-
rhage (n = 1, 6.3%), and petechiae (n = 1, 6.3%). All hemor-
rhagic events were of grade 1 or 2 and considered non-serious.
Five patients (31.3%) had serious AEs which included disease
progression (n = 3, 18.8%), leukocytosis, sepsis, and hyper-
uricemia (n = 1, 6.3% each). One patient (6.3%) discontinued
treatment and two (12.5%) had dose reduction due to at least
one AE. No patient discontinued treatment due to hemorrhagic
treatment-emergent AEs. Five patients (31.3%) with AEs died
due to disease progression before data cut-off. There were no
notable differences in the incidence of AEs between any of the
comparison subgroups (age, sex, the number of prior lines of
treatment, and liver function abnormality at baseline).
Discussion
In this multicenter phase II study, Japanese patients with
relapsed or refractory MCL were treated with ibrutinib at
560 mg/day. Prior to study entry, all patients had received
rituximab and half of the patients had received bendamustine,
including 3 patients with radiotherapy. The dose selected for
this study was based on data from a previous pivotal phase II
study in Europe, South and North America, Korea and Taiwan
and a phase I study in a Japanese patient group.(5,14,16) Mantle
cell lymphoma is predominantly a disease of elderly
patients,(3,6) and the age distribution of the study participants
(≥65 years, 75%; median, 72 years) represented the real world
population. Single agent ibrutinib therapy showed a favorable
benefit–risk profile, consistent with other studies reported in
non-Japanese populations.(5,14,16)
The ORR reported in this study (87.5%) was in agreement
with the findings of non-Japanese phase II (n = 111,
ORR = 67.0%) and phase III (n = 280, ORR = 71.9%) studies
of ibrutinib.(14,15) The response rate achieved was irrespective
of baseline characteristics like age, sex, simplified Mantle Cell
Lymphoma International Prognostic Index score, number of
prior therapies, or baseline refractory disease. These results
support the findings of the phase I Japanese study of ibrutinib
in patients with B-cell malignancies, with two MCL patients
who responded to ibrutinib treatment (n = 15, combined
ORR = 73.3%).(16)
Bortezomib and lenalidomide, two newer agents approved
by the US FDA for the treatment of relapsed or refractory
MCL, have reported ORRs of 33.0% (n = 155) (bortezomib)
and 28.0% (n = 134) (lenalidomide) in pivotal studies carried
out among non-Japanese patient groups.(7,8) Although not
investigated in the same study, the ORR obtained with ibruti-
nib in this study (i.e., 87.5%) may offer intriguing prospects.
However, the shorter follow-up and the wide range of CI war-
rant a cautious interpretation of results.
The median time to initial response (1.8 months) reported in
this study was consistent with the previous pivotal phase II
study (1.9 months).(5,14) The median time to initial response
for bortezomib was reported to be 1.3 months and for lenalido-
mide, 2.2 months.(7,8)
The safety profile of ibrutinib was acceptable and consistent
with the known safety profile of ibrutinib in B-cell malignan-
cies with no unexpected AEs being reported in this study.
Diarrhea was the most common AE (37.5%), which was con-
sistent with the findings of earlier studies.(14,16) All-grade
bleeding events were reported in 31.3% patients (all ≤ grade
3) compared to an incidence rate of 50.0% reported previ-
ously.(14) No subdural hematoma events were reported. The
most common all-grade hematological events that occurred in
this study were neutropenia (6.3%), anemia (25.0%), and
thrombocytopenia (18.8%). The incidence rate of neutropenia
was lower than that reported earlier (19.0%) in patients with
B-cell malignancies.(16) The incidence rates of anemia (18%)
and thrombocytopenia (22%) were comparable with the pivotal
phase II study.(14) Incidence of any-grade stomatitis in this
study was higher (37.5%) than that reported in the phase I
Fig. 2. Waterfall chart for maximum reduction in
the sum of the products of diameters of
measurable lesions (SPD) in Japanese patients with
relapsed or refractory mantle cell lymphoma
treated with ibrutinib, as determined by the study’s
Independent Review Committee (response-
evaluable population, n = 16).
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Japanese study of ibrutinib (overall 20.0%),(10) however, the
majority of stomatitis events were ≤ grade 3. Nevertheless, the
smaller sample size is a limitation of the study that may con-
tribute to higher reported rates of AEs.
Bendamustine, a newer cytotoxic i.v. agent, has reported
efficacy as a single-agent therapy for treatment of B-cell non-
Hodgkin’s lymphomas including relapsed or refractory MCL
among Japanese patients.(10) However, a high number of
patients experienced grade 3 or higher hematological AEs
compared to the present study (neutropenia [72.0% vs 6.3%]
and thrombocytopenia [16.0% vs 0.0%]).(10) One patient
(6.3%) in this study experienced lymphocytopenia that was not
severe.
In this study, orally administered single agent ibrutinib was
found to be efficacious with an acceptable safety profile in
Japanese patients with relapsed or refractory MCL. The high
overall response achieved in this study along with the accept-
able toxicity profile is in agreement with phase II and III stud-
ies of ibrutinib completed to date. Ibrutinib may provide a less
intensive and potentially more effective treatment option for
patients who are ineligible for intensive treatment approaches.
Acknowledgments
The authors thank Norio Komatsu (Juntendo University School of
Medicine, Tokyo, Japan) for participating in this study as a member of
the Safety Monitoring Committee, Rishabh Pandey (SIRO Clinpharm
Pvt. Ltd.) for writing assistance, and Dr. Namit Ghildyal (Janssen
Research and Development, LLC) for additional review and editorial
assistance. The authors thank all the patients, their families, investiga-
tors, review committee members, medical experts, nurses, and clinical
research coordinators who participated in this clinical trial.
Disclosure Statement
T.N. and S.T. are employees of Janssen Pharmaceutical. H.N. received
honoraria from Chugai; K.T. from Zenyaku, Eisai, Spectrum, Takeda,
and Mundipharma; D.M. from Takeda and Janssen; K.H. from Kyowa
Hakko Kirin, ONO, Takeda, and Celgene; and T.U. from Janssen.
H.N. received research funding from CMIC, Celgene, Janssen, Mundi-
pharma, Takeda, Servier, and Otsuka; K.T. and D.M. from Chugai,
Kyowa Hakko Kirin, ONO, Celgene, Janssen, GlaxoSmithKline, Eisai,
Mundipharma, Takeda, Servier, and Abbvie; K.H. from Kyowa Hakko
Kirin and Takeda; T. Kinoshita from Chugai, Takeda, ONO, and
Gilead Sciences. The study was funded by Janssen Pharmaceutical.
The study was designed under the responsibility of Janssen Pharmaceu-
tical, in conjunction with the steering committee. All authors had full
access to all the data in the study and had final responsibility for the
decision to submit for publication. All authors met the International
Council of Medical Journal Editors’ criteria for authorship, and anyone
who met those criteria is listed as an author. All authors have read and
approved the final manuscript for submission. The other authors have





DOR duration of response
ECOG Eastern Cooperative Oncology Group
IRC Independent Review Committee
MCL mantle cell lymphoma





TTR time to response
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